Fremanezumab in the prevention of migraine: a profile of its use

<p><b>Compliance with ethical standards</b></p><p><b><br></b></p> <p><i>Funding</i>: The preparation of this review was not supported by any external funding.</p><p><br></p> <p><i>Conflicts of interest:</i> Y. N. Lamb is a salaried employee of Adis International Ltd./Springer Nature, is responsible for the article content and declares no conflicts of interest.</p><p><br></p><p></p><p>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a><b></b></p><p><br></p><p>Abstract</p><p><br></p><p>Fremanezumab (fremanezumab-vfrm; Ajovy®), a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), is indicated for the prevention of migraine in adults in the EU and USA. Subcutaneous fremanezumab 225 mg once monthly or 675 mg once every 3 months was effective in reducing monthly migraine days or headache days in patients with episodic or chronic migraine in pivotal, 12-week clinical trials. Both regimens also reduce acute headache medication use and headache-related disability. Improvements were maintained through ≤ 52 weeks of additional treatment in a longer-term extension study. In a trial in treatment-resistant migraine, both fremanezumab regimens reduced monthly migraine days in patients who had failed 2–4 classes of preventive medications. Fremanezumab is generally well tolerated, with most adverse events (AEs) being injection site reactions of mild or moderate severity. <br></p><p><br></p><p>© Springer Nature Switzerland AG 2019<br></p>